Cytori Therapeutics' (CYTX) Study Finds Adipose Derived Stem, Regenerative Cells Significantly Reduce Mortality, Kidney Damage

February 25, 2009 9:23 AM EST

Cytori Therapeutics, Inc. (NASDAQ: CYTX) finds adipose tissue-derived stem and regenerative cells significantly reduce mortality and improve renal function in an acute kidney injury model. The preclinical results were reported today at the 14th Annual International Conference on Continuous Renal Replacement Therapies.

Acute kidney injury is a tremendous medical and financial burden to the healthcare system due to high mortality rates and the lack of effective therapies beyond supportive treatments. However, these new study findings by Cytori may lead to new therapeutic treatments using ADRCs that could reduce morbidity and mortality associated with acute kidney injury. Although this study was performed using a manual extraction technique, this potential application could be made more efficient and cost effective with the use of Cytori's Celution(R) System to isolate clinical grade ADRCs in real time.

As part of the study design, acute kidney injury was induced in 29 preclinical research subjects by occluding blood flow into and out of both kidneys for 38 minutes. Twenty minutes after reperfusion of the kidneys, ADRCs or saline only were injected intra-arterially. All subjects were assessed daily for 7 days for markers of kidney function (serum creatinine and blood urea nitrogen) and survival.

After seven days, 100% of ADRC-treated preclinical subjects survived compared to only 57% in the control group (p<0.01). The ADRC-treated subjects also showed statistically significant improvements in kidney function, as measured by serum creatinine (p<0.0001) and blood urea nitrogen levels (p<0.0001). In addition, substantial improvement in the histologic structure within the kidney was observed, as measured by a reduction in tubular cell death and epithelial shedding (p<0.0001). This study suggests that ADRCs significantly accelerate renal repair and preserve renal function, offering a potential therapeutic approach in renal reparative medicine.

Kidney disease represents an annual cost of greater than $32 billion. More than 300,000 Americans are diagnosed with acute kidney injury annually, facing prolonged hospitalization, marked increases in morbidity as well as mortality.

Related Categories

Corporate News

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?